Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05102019 · ClinicalTrials.gov registry record · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
A NA study of Refractory Angina, sponsored by Shockwave Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT05102019 is a NA study of Refractory Angina that is actively recruiting participants, run by Shockwave Medical. The registered enrollment target is 380 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT05102019, a NA study of Refractory Angina, is actively recruiting participants, sponsored by Shockwave Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in selected subjects with reversible myocardial ischemia in the distribution of the right coronary artery and who are deemed unsuitable for revascularization, subjects without documented obstructive coronary disease and abnormal coronary flow reserve (ANOCA), and subjects who cannot complete an exercise tolerance test due to lower limb amputation (above the ankle) or other physiologic condition with documented chronic mobility or balance issues that require the use of a walking aid.
Conditions Studied
Interventions
- DEVICE Arm 1: treatment with Shockwave Reducer
- OTHER Arm 2 (control): Implantation procedure with no device implanted
- DEVICE Arm 3 (unblinded, non-randomized): Single arm registry
Study Locations (20)
Florida
- The Cardiac and Vascular Institute - Gainesville
- UF Health Jacksonville - Jacksonville
- Mount Sinai Miami - Miami Beach
- NCH Healthcare - Naples - Naples
- Ascension Sacred Heart - Pensacola
- Tallahassee Research Institute - Tallahassee
- Tampa General - USF Cardiology - Tampa
California
- Long Beach VA Medical Center - Long Beach
- Cedars-Sinai - Los Angeles
- UCSD - San Diego
- Kaiser Permanente San Francisco - San Francisco
- UCSF - San Francisco
- Los Robles Hospital and Medical Center - Thousand Oaks
Arizona
- Mayo Clinic - Phoenix
- HonorHealth Research Institute - Scottsdale
- University of Arizona Sarver Heart Center - Tucson
Colorado
- South Denver Cardiology Associates - Littleton
Connecticut
- Yale University - New Haven
District of Columbia
- MedStar Cardiovascular Research Network - Washington D.C.
Georgia
- Emory Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2032-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05102019
The ClinicalTrials.gov registry entry for NCT05102019 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shockwave Medical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Angina appearing as the primary indexed condition, and to 3 interventions - of which Arm 1: treatment with Shockwave Reducer is the first listed.
NCT05102019 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05102019 about?
NCT05102019 is a clinical study titled "Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II". To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coro...
What is the current status of trial NCT05102019?
This trial is currently recruiting. It is a NA study. The enrollment target is 380 participants. The study started on 2022-01-04. Estimated completion is 2032-01.
What conditions does trial NCT05102019 study?
This clinical trial studies the following conditions: Refractory Angina.
What interventions are being tested in trial NCT05102019?
The interventions under investigation include: Arm 1: treatment with Shockwave Reducer (DEVICE), Arm 2 (control): Implantation procedure with no device implanted (OTHER), Arm 3 (unblinded, non-randomized): Single arm registry (DEVICE).
Who is sponsoring clinical trial NCT05102019?
This trial is sponsored by Shockwave Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05102019 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Angina
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.